T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 Pharmaceutical Research Report 2017

Market Research Hub (MRH) has recently publicized a new study to its vast repository, which is titled as “T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017”. According to the recently published report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017';

Request For Sample Report: http://www.marketresearchhub.com/enquiry.php?type=S&repid=1305500

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. 

T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - T-Cell surface glycoprotein CD3 epsilon chain also known as CD3E is a polypeptide encoded by the CD3E gene. T-cell surface glycoprotein CD3 epsilon chain interacts with TOP2B, CD3EAPand NCK2. The CD3 complex mediates signal transduction, resulting in T-cell activation and proliferation. 

The report 'T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3Leu 4 Epsilon Chain or CD3E) - Pipeline Review, H2 2017' outlays comprehensive information on the T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II and Preclinical stages are 3 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Metabolic Disorders, Central Nervous System, Gastrointestinal and Infectious Disease which include indications Type 1 Diabetes (Juvenile Diabetes), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Autoimmune Disorders, Chronic Inflammation, Crohn's Disease (Regional Enteritis), Hepatitis B, Inflammatory Bowel Disease, Kidney Transplant Rejection, Multiple Myeloma (Kahler Disease), Multiple Sclerosis, Non-Alcoholic Steatohepatitis (NASH), Primary Biliary Cirrhosis, Psoriasis and Rheumatoid Arthritis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- The report reviews T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics and enlists all their major and minor projects 
- The report assesses T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Browse Full Report With TOC: http://www.marketresearchhub.com/report/t-cell-surface-glycoprotein-cd3-epsilon-chain-t-cell-surface-antigen-t3leu-4-epsilon-chain-or-cd3e-pipeline-review-h2-2017-report.html

Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Overview 6
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Development 7
Products under Development by Stage of Development 7
Products under Development by Therapy Area 8
Products under Development by Indication 9
Products under Development by Companies 10
Products under Development by Universities/Institutes 12
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Therapeutics Assessment 14
Assessment by Mechanism of Action 14
Assessment by Route of Administration 16
Assessment by Molecule Type 18
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Companies Involved in Therapeutics Development 20
Amgen Inc 20
GlaxoSmithKline Plc 20
MacroGenics Inc 21
Numab Innovation AG 21
SYNIMMUNE GmbH 22
Tiziana Life Sciences Plc 22
T Cell Surface Glycoprotein CD3 Epsilon Chain (T Cell Surface Antigen T3/Leu 4 Epsilon Chain or CD3E) - Drug Profiles 23
Bispecific Monoclonal Antibodies to Target CD3, CD16 and HBsAg for HBV Infection and Oncology - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
foralumab - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
ND-007 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
otelixizumab - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
TACSYN - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
teplizumab - Drug Profile 30
Product Description 30

Make an Enquiry: http://www.marketresearchhub.com/enquiry.php?type=enquiry&repid=1305500

About Market Research Hub

Market Research Hub (MRH) is a next-generation reseller of research reports and analysis. MRH’s expansive collection of market research reports has been carefully curated to help key personnel and decision makers across industry verticals to clearly visualize their operating environment and take strategic steps.

MRH functions as an integrated platform for the following products and services: Objective and sound market forecasts, qualitative and quantitative analysis, incisive insight into defining industry trends, and market share estimates. Our reputation lies in delivering value and world-class capabilities to our clients.

Contact Us
90 State Street,
Albany, NY 12207,
United States
Toll Free : 800-998-4852 (US-Canada)
Email : press@marketresearchhub.com
Website : http://www.marketresearchhub.com/
Read Industry News at - https://www.industrynewsanalysis.com/

This release was published on openPR.